return equiti ttm
quarter unchang guidanc
fine-tun estim iqvia follow first-quart earn releas
wednesday morn quarter result impress better-than-expect
revenu driven technolog analyt solut ta segment improv
ebitda margin guidanc maintain interpret better first quarter
off-set fx headwind impact larg
market perform cancel total maintain revenu ep
target full year although assumpt chang note
overal view result encourag start year
evid demand stabl strong broader pharma outsourc
servic space
iqv first-quart result expect top bottom line
million respect book well expectationsund
quarterli book-to-bil ratio time versu estim net
award roughli year-ago level organ revenu solut
declin sequenti howev manag note
headwind pass-through suggest underli growth segment stabl
still expect full-year step-up organ growth last year year
 organ growth ta contract sale medic solut
improv sequenti respect illustr exhibit iqv
consolid organ revenu growth second best seen sinc
merger complet indic view compani regain share
maintain revenu estim billion total
organ constant currenc ep estim expect
underli organ growth ta segment around previou
estim segment expect organ revenu growth
compar previous driven cancel
pass-through headwind higher growth ta particular good news
margin leverag sinc iqv profit segment thu remain quit
comfort continu gener midteen ep growth maintain
outperform rate view current rel valuat reason
iqvia integr inform technology-en healthcar servic provid annual revenu base
approach billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
exhibit iqvia estim consolid organ growth present
segment observ expect
technolog analyt solut increas bit organ constant-curr basi quarter
compar target total revenu segment beat model million driven mainli sever
smaller acquisit ad approxim percentag point growth manag commentari suggest
better-than-expect growth driven strong perform orchestr custom engag oce
platform new product model roughli organ growth
 increas organ constant currenc basi quarter target manag
note much smaller pass-through revenuesan artifact convers standardreduc organ
growth basi point compani gener net book-to-bil ratio roughli quarter
month ratio year-over-year backlog growth inclus larg cancel
metric give us addit comfort cro gain share first quarter strong
book suggest higher pace revenu growth abl carri rest beyond
expect organ growth reflect impact larg disclos cancel
reduc servic revenu million next year
contract sale medic solut decreas constant-curr basi first quarter continu
sequenti improv result miss expect million manag indic expect
busi return growth back half year model small declin segment full year
slight return growth
maintain consolid revenu billion maintain ep estim
lower ebitda margin expect basi point howev decreas
interest expens assumpt result chang ep growth
valuat stock thought
trade time unchang ep estim slightli cro group averag
multipl time maintain outperform rate given encourag sign revenu acceler
strong book despit larg cancel updat model iqvia follow exhibit
xxsourc compani report william blair william blair
exhibit updat iqvia hold incom statement summari
profit gener administr expens amort incom includ option beg incom expens tax investe non-controlling interests/minor hedg incom item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross rate revenu begin excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
